Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Official record

Identifier

NCT06459024

Recruiting locations

countries

GermanyItalyLithuaniaPolandRomaniaSpain

Interventions studied

Registration into the STREAM platform

Lead sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Target enrolment

4000 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Recruiting

First posted

Jun 14, 2024

Last updated on the registry

Aug 14, 2026

Age

6 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Patients with AML diagnosis according to WHO2022 or ICC2022
* Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria
* Participant or his/her legal representative is willing and able to give informed consent for participation in the study

Exclusion Criteria:

* Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.

Indexed under

Leukemia